Search results
Results from the WOW.Com Content Network
In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [31] under the brand name Prolia, [32] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [33] Denosumab is the first RANKL inhibitor to be approved by the FDA. [31]
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
Although the total United States prescriptions for oral bisphosphonates exceeded 30 million in 2006, less than 10% of MRONJ cases were associated with patients taking oral bisphosphonate drugs. [23] Studies have estimated that BRONJ occurs in roughly 20% of patients taking intravenous zoledronic acid for cancer therapy and in between 0–0.04% ...
Of the estimated 10 million Americans with osteoporosis, more than 8 million (or 80%) are women. ... of medicine to prevent or treat osteoporosis include: Bisphosphonates. ... vitamins) better ...
Alendronate, a common bisphosphonate drug, has a three carbon length side chain for example. [17] Risedronate has heterocyclic structure containing nitrogen. Heterocyclic nitrogen containing bisphosphonates have revealed better results in terms of activity compared to earlier bisphosphonates with nitrogen bound to carbon chain. Studies on ...
Although an effective treatment for bisphosphonate-associated bone lesions has not yet been established, [39] and this is unlikely to occur until this form of ONJ is better understood, there have been clinical reports of some improvement after 6 months or more of complete cessation of bisphosphonate therapy. [40]
Prolia, approved in 2010 to treat bone loss in postmenopausal women and later approved to treat men and women at high risk of fracture, brought in total third-quarter sales of $986 million.
Bisphosphonates are popular drugs for treatment of osteoporosis. [1] Clodronic acid is a bisphosphonate used as a drug to treat osteoporosis. In biochemistry and medicinal chemistry, phosphonate groups are used as stable bioisosteres for phosphate, such as in the antiviral nucleotide analog, Tenofovir, one of the cornerstones of anti-HIV therapy.